Discovery of Novel c-Jun N-Terminal Kinase 1 Inhibitors from Natural Products: Integrating Artificial Intelligence with Structure-Based Virtual Screening and Biological Evaluation
c-Jun N-terminal kinase 1 (JNK1) is currently considered a critical therapeutic target for type-2 diabetes. In recent years, there has been a great interest in naturopathic molecules, and the discovery of active ingredients from natural products for specific targets has received increasing attention...
Main Authors: | Ruoqi Yang, Guiping Zhao, Bin Yan |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-09-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/27/19/6249 |
Similar Items
-
The Roles of c-Jun N-Terminal Kinase (JNK) in Infectious Diseases
by: Jing Chen, et al.
Published: (2021-09-01) -
C-Jun N-terminal kinase inhibitors: Structural insight into kinase-inhibitor complexes
by: Men Thi Hoai Duong, et al.
Published: (2020-01-01) -
c-Jun N-Terminal Kinase Phosphorylation Is a Biomarker of Plitidepsin Activity
by: Alberto Muñoz, et al.
Published: (2013-05-01) -
EFFECT OF SAHA AND C-JUN N-TERMINAL KINASE INHIBITOR ON THE INDUCIBLE MRNA EXPRESSION OF INTERLEUKIN-17
by: Boncho Grigorov, et al.
Published: (2023-09-01) -
Identification of potential extracellular signal-regulated protein kinase 2 inhibitors based on multiple virtual screening strategies
by: Ruoqi Yang, et al.
Published: (2022-11-01)